• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by CollPlant Biotechnologies Ltd

    11/26/25 7:38:38 AM ET
    $CLGN
    Industrial Specialties
    Health Care
    Get the next $CLGN alert in real time by email
    6-K 1 ea0267204-6k_collplant.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

    Commission File Number 001-38370

     

    CollPlant Biotechnologies Ltd.

    (Exact name of registrant as specified in its charter)

     

    4 Oppenheimer St, Weizmann Science Park

    Rehovot 7670104, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

    On November 26, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “Collplant Biotechnologies Reports 2025 Third Quarter Financial Results and Provides Corporate Update”.

     

    Attached hereto and incorporated by reference herein are the following exhibits:

     

    99.1   Press Release, dated November 26, 2025

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      COLLPLANT BIOTECHNOLOGIES LTD.
           
    Date: November 26, 2025 By: /s/ Eran Rotem
        Name: Eran Rotem
        Title: Deputy CEO and Chief Financial Officer

     

     

    2

     

     

    Get the next $CLGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLGN

    DatePrice TargetRatingAnalyst
    2/17/2023$22.75Buy
    Alliance Global Partners
    More analyst ratings

    $CLGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

    Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this regionRecent developments suggest CollPlant's rhCollagen will have a significant contribution towards innovation in the areas of non-animal alternatives for medical and researchPlan for cost reductions and program prioritization in place to extend cash runwayREHOVOT, Israel, Nov. 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its n

    11/26/25 7:30:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

    REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhColla

    11/18/25 7:00:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

    -- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel, Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the expansion of its distribution footprint into North America through a new partnership with a U.S.-based logistics center. Scheduled to become operational this quarter, the logistics hub will provide full cGMP-compliant storage and distribution services and will serve as a cl

    10/27/25 7:01:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    $CLGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on CollPlant with a new price target

    Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75

    2/17/23 8:30:35 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

    HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously

    2/9/21 6:08:53 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    $CLGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by CollPlant Biotechnologies Ltd

    SCHEDULE 13D/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

    11/28/25 6:03:31 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by CollPlant Biotechnologies Ltd

    6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

    11/26/25 4:15:26 PM ET
    $CLGN
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by CollPlant Biotechnologies Ltd

    6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

    11/26/25 7:38:38 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    $CLGN
    Leadership Updates

    Live Leadership Updates

    View All

    CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

    New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platform

    7/14/25 7:00:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

    Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

    5/23/22 8:00:00 AM ET
    $CFRX
    $CLGN
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    RION Appoints Alisa Lask as Chief Commercial Officer

    - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

    1/14/22 9:00:00 AM ET
    $CLGN
    $NEPH
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $CLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

    SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

    2/13/24 4:01:04 PM ET
    $CLGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

    SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

    1/25/24 3:27:05 PM ET
    $CLGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

    SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

    7/24/23 6:27:46 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    $CLGN
    Financials

    Live finance-specific insights

    View All

    COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

    REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhColla

    11/18/25 7:00:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

    REHOVOT, Israel, Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (reco

    8/5/25 7:00:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care

    COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

    REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina

    5/14/25 7:00:00 AM ET
    $CLGN
    Industrial Specialties
    Health Care